跳至主要内容
临床试验/NL-OMON34282
NL-OMON34282已完成不适用

Two-Center, In-Patient, Randomized, Placebo and Active Comparator Evaluation of the Pharmacokinetics (PK) and Safety, Along with Initial Pharmacodynamic (PD) Efficacy of Three Dose Levels of TBS-2 Intranasal Gel Applied Twice-Daily (BID) for up to Three Days in Female Patients with Hypoactive Sexual Desire Disorder (HSDD) or Anorgasmia (ANOR). - Eval. PK /Safety of TBS-2 Intranasal in Fem. Pat. with HSDD/ANOR

Trimel Biopharma SR0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Females up to 65 years
  • HSDD with personal distress
  • BMI equal to or less than 35
  • Women must have a score of >11 on the FSDS-R

排除标准

  • History of any clinically relevant other psychiatric disorders that could impact sexual function
  • History of Major Depressive Disorder within 6 months prior to study
  • Patients who meet DSM-IV criteria for Sexual Aversion Disorder, Substance-Induced Sexual Dysfunction, Dyspareunia (not caused by inadequate foreplay stimulation or alleviated by lubricants), Vaginismus, Gender Identity Disorder, Paraphilia, or for Sexual Dysfunction Due to a General Medical Condition.
  • Patients with pelvic inflammatory disease, urinary tract or vaginal infection

研究者

发起方
Trimel Biopharma SR

相似试验